4SC 203

Drug Profile

4SC 203

Alternative Names: 4SC-203; SC71710

Latest Information Update: 09 Oct 2013

Price : $50

At a glance

  • Originator 4SC; ProQinase
  • Developer 4SC
  • Class Antineoplastics; Inositol phosphates; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Focal adhesion protein-tyrosine kinase inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Solid tumours

Most Recent Events

  • 14 May 2013 Discontinued - Phase-I for Acute myeloid leukaemia (in volunteers) in Germany (IV)
  • 14 May 2013 Discontinued - Preclinical for Solid tumours in Germany (IV)
  • 07 Jan 2011 Preclinical trials in Solid tumours in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top